[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hua Jiang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":98},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100633941","phase-2-intestinal-microbiota-transplantation-for-treating-advanced-tumor-cachexia-100633941",false,"NCT07533227","Intestinal Microbiota Transplantation for Treating Advanced Tumor Cachexia","Intestinal Microbiota Transplantation for Treating Advanced Tumor Cachexia: A Prospective, Multicenter, Single-arm, Phase II Clinical Study","FMT-CACH","Inclusion Criteria:\n\n1. Pre-advanced or advanced tumor cachexia stage.\n2. Age ≥ 18 years old, ECOG score 0-2, expected survival \\> 3 months.\n3. Patients with gastric cancer, colorectal cancer, or lung cancer who have received second-line or higher treatment.\n4. No FMT treatment in the past six months.\n\nExclusion Criteria:\n\n1. Any condition that affects gastrointestinal absorption, such as difficulty in swallowing, malabsorption, or uncontrollable vomiting; undergoing tube feeding or parenteral nutrition.\n2. Neurotic anorexia, anorexia caused by mental illness, or difficulty in eating due to pain.\n3. Acquired immunodeficiency syndrome.\n4. Currently taking or planning to take other drugs that increase appetite or weight, such as adrenal corticosteroids (except for short-term use of dexamethasone during chemotherapy), androgens, progestogens, salidroside, olanzapine, and anamorin or other appetite stimulants.\n5. Patients with Cushing's syndrome, adrenal or pituitary insufficiency; patients with difficult-to-control diabetes.\n6. Current imaging or clinical manifestations of gastrointestinal obstruction.\n7. Current uncontrolled coexisting diseases, including but not limited to decompensated cirrhosis, renal failure, uncontrolled metabolic disorders, severe active peptic ulcer disease or gastritis, or mental illnesses\u002Fsocietal conditions that may limit patient compliance with study requirements or affect the patient's ability to provide written informed consent.\n8. Within 12 months prior to the first administration, there was unstable angina pectoris, myocardial infarction, congestive heart failure (grade 2 or above according to the New York Heart Association functional classification), or vascular diseases (such as aneurysms with a risk of rupture), or other cardiac damages that may affect the safety evaluation of the study drug (such as poorly controlled arrhythmias, myocardial ischemia); within 6 months prior to the first administration, there was esophageal-gastric varices, severe ulcers, gastrointestinal perforation and\u002For fistula history, history of gastrointestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), intra-abdominal abscess or history of acute gastrointestinal bleeding.\n9. Within 4 weeks prior to the first administration, a serious infection occurred, including but not limited to conditions requiring hospitalization.","ALL","18 Years",{"count":20,"type":21},66,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This project is a prospective, multicenter, single-arm, phase II clinical study aimed at evaluating the efficacy and safety of fecal microbiota transplantation (FMT) in treating advanced tumor cachexia.",[27,28],"Cachexia; Cancer","Fecal Microbiota Transplantation (FMT)",[30,31,32],"cachexia","FMT","Fecal Microbiota Transplantation","NOT_YET_RECRUITING","2026-04-14",{"date":36,"type":37},"2026-04-16","ACTUAL",{"date":39,"type":21},"2026-05-01",{"date":41,"type":21},"2027-05-01",{"name":43,"class":44},"Hua Jiang","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100577697","phase-2-fmt-ql1706bevacizumab-xelox-as-first-line-treatment-for-advanced-mss-type-colon-cancer-with-liver-metastasis-100577697","NCT06801665","FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis","Fecal Microbiota Transplantation Combined With QL1706, Bevacizumab, and XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis: A Prospective, Multi-center, Single-arm Phase II Study","Inclusion Criteria:\n\n1. Histological or cytological confirmed advanced colon cancer with liver metastasis.\n2. Signed written informed consent.\n3. Have not received anti-tumor treatment.\n4. According to the investigators assessment, at least one measurable target lesion defined by RECIST v1.1.\n5. Patients of both sexes, aged ≥18 years and ≤75 years.\n6. ECOG PS 0-1;\n7. Expected survival time ≥ 3 months;\n8. Have adequate organ and bone marrow function, laboratory examination within 7 days prior to enrollment meets the following requirements, as follows:\n\n1\\) Blood routine: ANC ≥ 1.5 × 10\\^9\u002FL, Platelet count ≥ 100 × 10\\^9\u002FL, HGB ≥100 g\u002FL (no blood transfusion or erythropoietin dependence within 14 days); 2) Liver function: TBIL ≤1.5 x ULN; ALT\u002FAST ≤ 5 x ULN; ALP ≤5×ULN; 3) Renal function: Cr ≤1.5×ULN, or creatinine clearance ≥50 mL\u002Fmin: Urine routine results showed urinary protein \\\u003C 2+; 4) Coagulation function: INR or PT ≤1.5 x ULN. 9.For female subjects of reproductive age, a urine or serum pregnancy test should be performed and the result is negative 3 days prior to receiving the initial study drug administration.\n\n10\\. For women of childbearing potential (WOCBP): agreement to refrain from heterosexual intercourse or use contraception.\n\n11\\. For men: agreement to refrain from heterosexual intercourse or use a condom, and agreement to refrain from donating sperm.\n\nExclusion Criteria:\n\n1. Suffered from other malignancies in the past 5 years, excluding cured basal cell carcinoma of the skin, cervical carcinoma in situ and papillary thyroid carcinoma.\n2. Patients requiring elective surgery during the trial.\n3. Patients who cannot take oral drugs, or have conditions that the investigator determines to significantly affect gastrointestinal absorption, such as chronic diarrhea, intestinal obstruction, etc., and are not suitable for treatment.\n4. Patients during pregnancy (positive pregnancy test) or lactation.\n5. Central nervous system metastasis or meningeal metastasis.\n6. Uncontrollable bone metastasis, or patients at risk of fracture, requiring surgery, local radiation therapy.\n7. Patients with active infection requiring systemic anti-infection treatment.\n8. Patients with a history of immunodeficiency, including those who are positive for HIV antibody tests.\n9. Patients with known, active autoimmune diseases.\n10. Patients with uncontrolled active hepatitis B, patients with hepatitis C virus infection (HCV antibody positive).\n11. A history of severe cardiovascular and cerebrovascular diseases, including but not limited to: severe arrhythmia, acute coronary syndrome within 6 months, congestive heart failure, aortic dissection, stroke, and T IA history.\n12. Severe bleeding events occur within half a year, or high bleeding risk factors such as active digestive tract ulcers and esophageal and gastric varices due to liver cirrhosis.\n13. Patients with diabetes who cannot be stably controlled by drugs (including insulin).\n14. Mental or language disorders that prevent communication with the patient;\n15. Patients participating in another clinical trial.\n16. MSI-H\u002F d MMR without immunotherapy; left colorectum of Ras, Raf wild-type.\n17. The investigator believes that the subject has other serious systemic diseases or other conditions that make him unsuitable for participation in this trial.","75 Years",{"count":54,"type":21},30,[24],"The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 30 patients with advanced colon cancer patients with liver metastasis who have not received prior treatment. This study plans to reconstruct intestinal microecology through fecal microbiota transplantation (FMT), and combine with QL1706+Bevacizumab+XELOX to enhance the anti-tumor immune effect at the same time, thereby improving the prognosis of colon cancer patients with liver metastasis.",[58],"Colon Cancer Liver Metastases","RECRUITING","2025-12-28",{"date":62,"type":37},"2026-01-02",{"date":64,"type":37},"2025-04-17",{"date":66,"type":21},"2027-02-01",{"name":43,"class":44},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":68},"100434273","laparoscopic-or-abdominal-radical-hysterectomy-for-cervical-cancerstage-ia1-with-lvsi-ia2-100434273","NCT04934982","Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)","A Multicenter Noninferior Randomized Controlled Study Comparing the Efficacy of Laparoscopic Versus Abdominal Radical Hysterectomy for Cervical Cancer (Stage IA1 With LVSI, IA2)","LAUNCH 1","Inclusion Criteria:\n\n1. Clinical diagnosis of squamous carcinoma of the cervix, adenocarcinoma, squamous adenocarcinoma (IA1 with lymphovascular interstitial invasion, stage IA2).\n2. Age ≥ 21 years and ≤ 70 years.\n3. Surgery type B and C (refer to Q-M surgical staging)\n4. Normal range of liver and kidney function and blood count (specific details below) Hemoglobin \\> 60g\u002FL Platelets \\> 70\\*109\u002FL Leukocytes \\> 3\\*109\u002FL Creatinine \\\u003C 50mg\u002FdL Transaminase abnormal indicators ≤ 3 Maximum value of transaminases not exceeding 3 times the corresponding normal value.\n5. No history of other malignancies.\n6. Non-pregnancy.\n7. Physical strength classification: Karnofsky score ≥ 60;\n8. Subjects voluntarily joined the study, signed the informed consent form, were compliant and cooperated with the follow-up.\n9. No psychiatric disorders and other serious immune system disorders (e.g. lupus erythematosus, myasthenia gravis, HIV infection, etc.) (Note: Maximum diameter measurement of cervical lesions is based on PET-CT, or CT, or MRI)\n\nExclusion Criteria:\n\n1. Those who are contraindicated for various surgeries and cannot undergo surgery.\n2. Patients who have received pelvic\u002Fabdominal radiotherapy irradiation or neoadjuvant chemotherapy for cervical cancer.\n3. Patients with recurrent cervical cancer\n4. Patients with CT, MRI or PET-CT suggesting suspicious metastasis of pelvic lymph nodes with maximum diameter \\>2cm after further improvement of preoperative examination.","FEMALE","21 Years","70 Years",{"count":81,"type":21},690,[83],"NA","The purpose of this study is to confirm whether there is a difference between laparoscopic radical hysterectomy (LRH) and abdominal radical hysterectomy (ARH) in patient survival for Cervical Cancer (Stage IA1 with LVSI, IA2)",[86],"Cervical Cancer",[86,88,89],"Abdominal Radical Hysterectomy","Laparoscopic Radical Hysterectomy","2021-11-02",{"date":92,"type":37},"2021-11-10",{"date":94,"type":37},"2021-09-24",{"date":96,"type":21},"2026-06",{"name":43,"class":44},""]